Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7O50

Crystal structure of human legumain in complex with Gly-Ser-Asn peptide

Summary for 7O50
Entry DOI10.2210/pdb7o50/pdb
DescriptorLegumain, GLY-SER-ASN, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (5 entities in total)
Functional Keywordsenzyme, cysteine protease, ligase, asparaginyl endopeptidase, substrate, hydrolase
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains4
Total formula weight62209.35
Authors
Dall, E.,Brandstetter, H. (deposition date: 2021-04-07, release date: 2021-09-22, Last modification date: 2024-10-16)
Primary citationDall, E.,Stanojlovic, V.,Demir, F.,Briza, P.,Dahms, S.O.,Huesgen, P.F.,Cabrele, C.,Brandstetter, H.
The Peptide Ligase Activity of Human Legumain Depends on Fold Stabilization and Balanced Substrate Affinities.
Acs Catalysis, 11:11885-11896, 2021
Cited by
PubMed Abstract: Protein modification by enzymatic breaking and forming of peptide bonds significantly expands the repertoire of genetically encoded protein sequences. The dual protease-ligase legumain exerts the two opposing activities within a single protein scaffold. Primarily localized to the endolysosomal system, legumain represents a key enzyme in the generation of antigenic peptides for subsequent presentation on the MHCII complex. Here we show that human legumain catalyzes the ligation and cyclization of linear peptides at near-neutral pH conditions, where legumain is intrinsically unstable. Conformational stabilization significantly enhanced legumain's ligase activity, which further benefited from engineering the prime substrate recognition sites for improved affinity. Additionally, we provide evidence that specific legumain activation states allow for differential regulation of its activities. Together these results set the basis for engineering legumain proteases and ligases with applications in biotechnology and drug development.
PubMed: 34621593
DOI: 10.1021/acscatal.1c02057
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.9 Å)
Structure validation

246704

PDB entries from 2025-12-24

PDB statisticsPDBj update infoContact PDBjnumon